Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein.

By H. Thomas, H. Coley. Cancer Control: Journal of the Moffitt Cancer Cente, 2003

831 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. (2016, background): “Due to low therapeutic response and high cell toxicity, these inhibitors were quickly replaced by a second generation of inhibitors (Bechtel et al., 2008; Koski et al., 2012; Thomas and Coley, 2003).”
The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. (2015, background): “everal nonspecific ABC transporter inhibitors such as elacridar nd biricodar are known to inhibit ABCB1 and ABCC1 (Bates et al., 002; Szakacs et al., 2006; Thomas and Coley, 2003).”
Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. (2008, background): “Recently it was demonstrated that it also is a substrate for Pgp drug efflux transporter [72-74].”